Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone for Neurodegeneration With Brain Iron Accumulation (NBIA)
NCT00907283Phase 2Unknown
- Sponsor
- Ospedali Galliera
- Start
- Nov 2008
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferiprone in Neurodegeneration with brain iron accumulation (NBIA), sponsored by Ospedali Galliera. Primary endpoints: Efficacy of chelator therapy on cerebral iron accumulations at 12 months and Safety of chelator therapy at 1 year. Status: unknown.
02
Drugs
deferiprone
03
Conditions
Neurodegeneration with brain iron accumulation (NBIA)
Beyond the preview
Go deeper on NCT00907283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00907283.